Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.
作者信息
Yun Hyun Don, Antony Marie Lue, Linden Michael A, Noble-Orcutt Klara E, Eckfeldt Craig E, Ustun Celalettin, Nelson Andrew C, Sachs Zohar
机构信息
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States; Division of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University, Chicago, IL, United States.
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
出版信息
Leuk Res. 2020 Aug;95:106404. doi: 10.1016/j.leukres.2020.106404. Epub 2020 Jun 11.
Abstract
摘要
相似文献
1
Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.
Leuk Res. 2020 Aug;95:106404. doi: 10.1016/j.leukres.2020.106404. Epub 2020 Jun 11.
2
MDS with del(5q) and associated cKIT D816V positive mastocytosis.
Pathology. 2012 Aug;44(5):492-3. doi: 10.1097/PAT.0b013e3283559d03.
3
Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
Chin Med J (Engl). 2019 Aug 20;132(16):2002-2003. doi: 10.1097/CM9.0000000000000355.
4
Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers.
Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.
5
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.
6
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.
Am J Hematol. 2012 Feb;87(2):191-3. doi: 10.1002/ajh.22208. Epub 2011 Nov 12.
7
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.
8
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
Am J Hematol. 2013 Mar;88(3):219-24. doi: 10.1002/ajh.23380.
9
Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Intern Med. 2009;48(22):1973-8. doi: 10.2169/internalmedicine.48.2294. Epub 2009 Nov 16.
10
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
Am J Hematol. 2009 Dec;84(12):790-4. doi: 10.1002/ajh.21561.
引用本文的文献
1
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411.
本文引用的文献
1
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.
Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17.
2
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.
Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28.
3
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
Leukemia. 2017 Sep;31(9):1962-1974. doi: 10.1038/leu.2016.377. Epub 2016 Dec 23.
4
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563.
5
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Haematologica. 2016 Oct;101(10):1190-1199. doi: 10.3324/haematol.2015.136002. Epub 2016 Jul 14.
6
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
7
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.
8
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.
9
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
10
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.
Leukemia. 2014 Feb;28(2):248-57. doi: 10.1038/leu.2013.192. Epub 2013 Jun 25.
Zotero 插件